The discovery and development of prasugrel

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Thienopyridine Derivatives

Background:

• Prasugrel is a third-generation thienopyridine antiplatelet medication.
• Approved by the FDA in 2009 for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).

Purpose of the Study:

• To summarize the preclinical profile of prasugrel.
• To review pharmacokinetics, pharmacodynamics, and pharmacogenomics of prasugrel.
• To highlight distinguishing features in efficacy and safety compared to other agents.

Main Methods:

• Review of published preclinical and clinical studies.
• Analysis of pharmacokinetic and pharmacodynamic properties.
• Evaluation of pharmacogenomic influences on prasugrel response.

Main Results:

• Prasugrel demonstrates a more rapid and potent antiplatelet effect than clopidogrel.
• Less interindividual variability in response observed with prasugrel.
• Increased risk of bleeding associated with prasugrel's potent effect and dosing.

Conclusions:

• Prasugrel's chemical structure facilitates efficient conversion to its active metabolite, enhancing efficacy.
• Higher bleeding risk necessitates careful consideration, particularly in high-risk patients.
• Identification of optimal dosing strategies is essential for balancing prasugrel's efficacy and safety profile.